Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Federal Trade Commission
McKinsey
Queensland Health
Mallinckrodt
Johnson and Johnson
Chinese Patent Office
Moodys
Harvard Business School

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,071,130

« Back to Dashboard

Which drugs does patent 8,071,130 protect, and when does it expire?

Patent 8,071,130 protects DUETACT and is included in one NDA.

This patent has twenty-six patent family members in twenty-three countries.
Summary for Patent: 8,071,130
Title:Solid preparation
Abstract: The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from "a solid preparation containing only an insulin sensitizer as an active ingredient". The solid preparation comprises "a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol" and "a part containing an active ingredient other than an insulin sensitizer".
Inventor(s): Kiyoshima; Kenichiro (Osaka, JP), Nakamura; Kenji (Osaka, JP), Kawano; Tetsuya (Osaka, JP), Misaki; Masafumi (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:12/086,700
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 8,071,130

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-001 Jul 28, 2006 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-002 Jul 28, 2006 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,071,130

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2005-370375Dec 22, 2005
PCT Information
PCT FiledDecember 21, 2006PCT Application Number:PCT/JP2006/326169
PCT Publication Date:June 28, 2007PCT Publication Number: WO2007/072992

International Family Members for US Patent 8,071,130

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 200731971 ➤ Try a Free Trial
Russian Federation 2426530 ➤ Try a Free Trial
Russian Federation 2008130074 ➤ Try a Free Trial
Peru 00192011 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
US Army
Daiichi Sankyo
Cerilliant
Fuji
Mallinckrodt
Covington
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.